This company has been marked as potentially delisted and may not be actively trading. OTCMKTS:AVMXY AVITA MED LTD/S (AVMXY) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About AVITA MED LTD/S Stock (OTCMKTS:AVMXY) 30 days 90 days 365 days Advanced Chart Get AVITA MED LTD/S alerts:Sign Up Key Stats Today's Range$7.89▼$7.8950-Day Range$7.89▼$7.8952-Week Range$1.06▼$8.58VolumeN/AAverage Volume183,275 shsMarket Capitalization$651.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAvita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.Read More… Receive AVMXY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVITA MED LTD/S and its competitors with MarketBeat's FREE daily newsletter. Email Address AVMXY Stock News HeadlinesCantor maintains Avita stock Overweight with $19 targetFebruary 14, 2025 | msn.comAvita medical director Suzanne Crowe buys $6,390 in stockJanuary 30, 2025 | msn.comTrump and Musk fight backIs there more to the Musk–Trump relationship than meets the eye? Jeff Brown thinks so — and he believes it has to do with a top-level initiative to build the ultimate military-grade AI system. He’s calling it the “AI Superweapon,” and he says it could soon become the center of global tech dominance. At the core of this initiative? A handful of companies tied to America’s most powerful tech platforms — and investors who act before this goes mainstream may have a rare early edge.April 20, 2025 | Brownstone Research (Ad)BTIG Reaffirms Their Hold Rating on Avita Medical (RCEL)January 13, 2025 | markets.businessinsider.comAvita Medical (RCEL) Gets a Buy from Lake StreetJanuary 9, 2025 | markets.businessinsider.comAvita Medical (RCEL) Receives a Hold from BTIGJanuary 7, 2025 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Avita Medical (RCEL)December 24, 2024 | markets.businessinsider.comAvita Medical Says FDA Approved Recell GO MiniDecember 23, 2024 | marketwatch.comSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:AVMXY CIKN/A Webwww.avitamedical.com Phone661-367-9170FaxN/AEmployees55Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.50 Quick Ratio5.33 Sales & Book Value Annual Sales$5.51 million Price / Sales118.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book30.35Miscellaneous Outstanding Shares82,620,000Free FloatN/AMarket Cap$651.87 million OptionableNot Optionable Beta1.28 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:AVMXY) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVITA MED LTD/S Please log in to your account or sign up in order to add this asset to your watchlist. Share AVITA MED LTD/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.